Compass Therapeutics Inc

CMPX | $1.52 2.01% 13K

(0.0% 1d) (-27.3% 1m) (-48.8% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (-54.28% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 209,135,540

Sec Filling | Patents | 26 employees

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

add to watch list Paper trade email alert is off